Neurogene (NGNE) Short Interest Ratio & Short Volume

Short interest is the volume of Neurogene shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 914,200 shares of NGNE short. 8.89% of Neurogene's shares are currently sold short. Learn More on Neurogene's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NGNE shares currently have a short interest ratio of 7.0. Learn More on Neurogene's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.89% of Neurogene's floating shares are currently sold short.

Neurogene saw a drop in short interest in the month of October. As of October 31st, there was short interest totaling 914,200 shares, a drop of 2.2% from the previous total of 934,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Neurogene currently has issued a total of 14,850,000 shares. Some of Neurogene's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Neurogene currently has a public float of 10,280,000 shares.

8.89% of Neurogene's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Neurogene: Nuvation Bio Inc. (4.94%), Immatics (5.60%), ArriVent BioPharma, Inc. (18.26%), 89bio, Inc. (5.07%), Evolus, Inc. (8.58%), Rapport Therapeutics (11.74%), Cronos Group Inc. (1.95%), Pliant Therapeutics, Inc. (11.87%), Kura Oncology, Inc. (16.39%), Tyra Biosciences, Inc. (6.06%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

Short selling NGNE is an investing strategy that aims to generate trading profit from Neurogene as its price is falling. NGNE shares are trading up $4.71 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Neurogene occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NGNE, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NGNE, twice per month. The most recent reporting period available is October, 31 2024.